Quarterly ResultMay 7, 2026, 07:08 AM
Korro Bio Raises $85M in Private Placement; Q1 Net Loss $19.6M
AI Summary
Korro Bio reported its first quarter 2026 financial results, including a net loss of $19.6 million. The company successfully executed an oversubscribed $85 million private placement, extending its cash runway into the second half of 2028. Key pipeline advancements include KRRO-121 remaining on track for regulatory filing in H2 2026 and a GalNAc-conjugated oligonucleotide for AATD achieving over 90% in vivo RNA editing, with a development candidate expected in Q2 2026.
Key Highlights
- Executed oversubscribed $85 million private placement.
- Cash, cash equivalents, and marketable securities reached $157.1 million as of March 31, 2026.
- Extended cash runway into the second half of 2028.
- Reported Q1 2026 net loss of $19.6 million, compared to $23.4 million in Q1 2025.
- Q1 2026 R&D expenses decreased to $12.9 million from $19.7 million in Q1 2025.
- GalNAc-conjugated AATD program achieved over 90% in vivo RNA editing.
- KRRO-121 regulatory filing expected in the second half of 2026.